Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer: Hokkaido Gastrointestinal Cancer Study Group HGCSG0303
A multicenter Open-label, single-arm, phase II clinical trial is conducted on patients with
histological stage IV gastric cancer given irinotecan plus S-1. The usefulness of this
regimens as 1st line therapy for gastric cancer was evaluated by the disease-free survival
rate (DFR), overall survival rate (OS), incidence and severity of adverse event.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
objective tumor response
Yoshito Komatsu, MD, PhD
Study Chair
Hokkaido Gastrointestinal Cancer Study Group
Japan: Ministry of Health, Labor and Welfare
HGCSG0303
NCT00209664
January 2004
December 2008
Name | Location |
---|